Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Unlimited Watchlists, Portfolios, Screeners, and other Barchart tools. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

G1 Therapeutics Inc (GTHX)

G1 Therapeutics Inc (GTHX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 347,587
  • Shares Outstanding, K 42,912
  • Annual Sales, $ 31,480 K
  • Annual Income, $ -148,350 K
  • 60-Month Beta 1.73
  • Price/Sales 7.38
  • Price/Cash Flow N/A
  • Price/Book 7.62
Trade GTHX with:

Options Overview Details

View History
  • Implied Volatility 121.59% ( +0.01%)
  • Historical Volatility 65.68%
  • IV Percentile 85%
  • IV Rank 50.62%
  • IV High 201.58% on 01/05/23
  • IV Low 39.58% on 05/27/22
  • Put/Call Vol Ratio 0.06
  • Today's Volume 88
  • Volume Avg (30-Day) 434
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 8,886
  • Open Int (30-Day) 7,186

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.79
  • Number of Estimates 5
  • High Estimate -0.68
  • Low Estimate -0.88
  • Prior Year -0.94
  • Growth Rate Est. (year over year) +15.96%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.88 +62.26%
on 01/06/23
8.40 -5.83%
on 02/02/23
+2.18 (+38.05%)
since 01/03/23
3-Month
4.88 +62.26%
on 01/06/23
9.22 -14.17%
on 11/14/22
-0.02 (-0.25%)
since 11/03/22
52-Week
3.84 +105.99%
on 06/16/22
17.49 -54.77%
on 09/14/22
-1.55 (-16.38%)
since 02/03/22

Most Recent Stories

More News
Big Developments Set to be Unveiled at This Year's San Antonio Breast Cancer Symposium (SABCS)

/PRNewswire/ -- USA News Group - A new study has revealed that women diagnosed with benign breast disease through screening have an almost double risk of...

ONC.TO : 2.48 (unch)
ONCY : 1.8100 (-1.63%)
LLY : 339.08 (+2.53%)
NEO : 12.55 (-1.10%)
ZYME : 9.48 (+2.49%)
GTHX : 7.91 (-2.35%)
Big Developments Set to be Unveiled at This Year’s San Antonio Breast Cancer Symposium (SABCS)

EQNX::TICKER_START (NASDAQ:ONCY),(NYSE:LLY),(NASDAQ:NEO),(NYSE:ZYME),(NASDAQ:GTHX) EQNX::TICKER_END

ONCY : 1.8100 (-1.63%)
ONC.TO : 2.48 (unch)
LLY : 339.08 (+2.53%)
NEO : 12.55 (-1.10%)
ZYME : 9.48 (+2.49%)
GTHX : 7.91 (-2.35%)
Biotech Sector to Unveil New Data and Developments at 2022 SABCS in San Antonio

USA News Group – A new study has revealed that women diagnosed with benign breast disease through screening have an almost double risk of acquiring breast cancer. The findings come ahead of this year’s...

ONCY : 1.8100 (-1.63%)
ONC.TO : 2.48 (unch)
LLY : 339.08 (+2.53%)
NEO : 12.55 (-1.10%)
ZYME : 9.48 (+2.49%)
GTHX : 7.91 (-2.35%)
G1 Therapeutics (GTHX) Reports Q3 Loss, Tops Revenue Estimates

G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 7.81% and 4.14%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

GTHX : 7.91 (-2.35%)
CTKB : 13.39 (+1.13%)
Is G1 Therapeutics (GTHX) Stock Outpacing Its Medical Peers This Year?

Here is how G1 Therapeutics (GTHX) and HealthEquity (HQY) have performed compared to their sector so far this year.

GTHX : 7.91 (-2.35%)
HQY : 60.04 (+1.94%)
Is G1 Therapeutics (GTHX) Outperforming Other Medical Stocks This Year?

Here is how G1 Therapeutics (GTHX) and HealthEquity (HQY) have performed compared to their sector so far this year.

GTHX : 7.91 (-2.35%)
HQY : 60.04 (+1.94%)
G1 Therapeutics (GTHX)'s Technical Outlook is Bright After Key Golden Cross

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

GTHX : 7.91 (-2.35%)
Can G1 Therapeutics (GTHX) Climb 150% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for G1 Therapeutics (GTHX) points to a 149.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among...

GTHX : 7.91 (-2.35%)
G1 Therapeutics, Inc. (GTHX) Q2 2022 Earnings Call Transcript

GTHX earnings call for the period ending June 30, 2022.

GTHX : 7.91 (-2.35%)
G1 Therapeutics (GTHX) Reports Q2 Loss, Tops Revenue Estimates

G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 11.54% and 17.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

GTHX : 7.91 (-2.35%)
EXEL : 17.55 (-0.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel, small-molecule therapies which address significant unmet needs in the treatment of cancer. The company's product pipeline consists of CDK4/6, Trilaciclib (G1T28), G1T38 and G1T48. G1 Therapeutics, Inc....

See More

Key Turning Points

3rd Resistance Point 8.44
2nd Resistance Point 8.27
1st Resistance Point 8.09
Last Price 7.91
1st Support Level 7.74
2nd Support Level 7.57
3rd Support Level 7.39

See More

52-Week High 17.49
Fibonacci 61.8% 12.28
Fibonacci 50% 10.66
Fibonacci 38.2% 9.05
Last Price 7.91
52-Week Low 3.84

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar